How Quitting Smoking Can Quickly Lower Risk Of A-Fib

Updated Sep 14, 2024 | 02:00 AM IST

SummaryNew research reveals that quitting smoking quickly reduces the risk of atrial fibrillation (A-Fib). Former smokers have a significantly lower risk compared to current smokers, emphasizing the health benefits of quitting.
How Quitting Smoking Can Quickly Lower Risk Of A-Fib

How Quitting Smoking Can Quickly Lower Risk Of A-Fib

Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.

Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."

What is Atrial Fibrillation (A-Fib)?

A-Fib is a heart condition that affects the upper chambers of the heart, known as the atria. When these chambers beat irregularly, blood can pool and form clots, increasing the risk of stroke. Stroke is one of the most serious complications associated with A-Fib, and smoking is known to exacerbate this risk.

"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.

The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.

"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.

The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.

Tips for Quitting Smoking

Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:

1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.

2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.

3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.

4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.

5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.

6. Drinking water can help flush nicotine out of your system faster, reducing cravings.

7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.

Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.

End of Article

Meningococcal B Vaccine Ineffective In Preventing Gonorrhea In Gay And Bisexual Men: Study

Updated Mar 2, 2026 | 11:06 AM IST

SummaryThe 4CMenB vaccine is a highly effective, protein-based vaccine that protects against invasive meningococcal disease, but offers no protection against gonorrhea. Gonorrhea causes an estimated 82.4 million new infections among adults globally.
Meningococcal B Vaccine Ineffective In Preventing Gonorrhea In Gay And Bisexual Men: Study

Credit: Canva

The meningococcal B vaccine (4CMenB) is completely ineffective in preventing gonorrhea -- a sexually transmitted infection (STI) --, especially among high-risk groups like gay and bisexual men, according to the results of the world’s largest randomized control trial (RCT).

Gonorrhea is a common bacterial STI caused by the bacterium Neisseria gonorrheae, and is transmitted through unprotected sex.

Even as antimicrobial resistance in gonorrhea has increased rapidly in recent years, Australian researchers explored the efficacy of 4CMenB against the disease.

The large randomized, placebo-controlled trial involving 587 gay and bisexual men showed that the risk of gonorrhea incidence remains essentially the same even after vaccination.

“Across both arms, the gonorrhea incidence was virtually the same -- at around 48 per cent per year, indicating very clearly that the vaccine had no effect on preventing gonorrhea,” said Professor Kate Seib, from Griffith University, in Australia, who led the trial.

In light of the study, the researchers stressed the need to explore other options to combat gonorrhea, such as condoms and regular testing.

The 4CMenB Vaccine

While meningococcal disease (caused by Neisseria meningitidis) and gonorrhea (caused by Neisseria gonorrhoeae) are distinct infections, both are caused by Neisseria bacteria, which share 80-90 percent genetic material.

The bacterium N. meningitidis primarily causes meningitis and septicemia, and observational studies have shown that meningococcal B (MenB) vaccines such as the 4CMenB offer 33-40 percent cross-protection against gonorrhea.

However, the latest study, presented at the Conference on Retroviruses and Opportunistic Infections in Denver, US, found no protection against gonorrhea.

The study “provides strong evidence that the 4CMenB meningococcal vaccine is not effective at preventing gonorrhea in gay and bisexual men who are at high risk of contracting it,” Seib said.

According to the US National Institute of Health, the 4CMenB vaccine is a highly effective, protein-based vaccine designed to protect against invasive meningococcal disease (IMD) serogroup B.

Approved in over 50 countries, it offers 71-95 percent effectiveness in infants and 100 percent in adolescents.

What Is Gonorrhea

Gonorrhea is a common STI, and sexually active people of any age can get the disease and pass it on to partners, and even to their baby during childbirth.

Gonorrhea is the second most common STI caused by bacteria, just behind chlamydia.

As per data from the World Health Organization (WHO), in 2020, there were an estimated 82.4 million new infections among adults globally.

The NIH noted that nearly 1 million new gonorrhea infections occur in the United States every year. About half of these infections occur in people ages 15 to 24.

The symptoms of Gonorrhea in men include:

  • White, yellow, or green discharge from the penis
  • Pain or burning (possibly severe) when peeing
  • Testicular pain and swollen testicles.

Notably, the condition also occurs in women, but up to 50 percent of them won’t experience symptoms. This increases the risk of spread to other partners.

  • Common symptoms in women include:
  • Unusual vaginal discharge (white or yellow).
  • Pain in your lower abdomen or pelvis.
  • Pain during sexual intercourse
  • Pain when you pee
  • Bleeding between periods

End of Article

Two Passengers From Singapore Airlines Arrive In New Zealand With Measles

Updated Feb 28, 2026 | 10:10 PM IST

SummaryTwo Singapore Airlines passengers from Hyderabad developed measles symptoms en route to Auckland after transiting in Singapore. Authorities confirmed no local link. Measles is highly contagious, requiring strong vaccination coverage. Health officials urge immunization, hygiene, and prompt reporting of symptoms.
Two Passengers From Singapore Airlines Arrive In New Zealand With Measles

Credits: Canva

Two passengers travelling in Singapore airlines arrived in New Zealand with measles symptoms. However, reported The Strait Times, that they are not linked to any other known cases, as noted by the Communicable Disease Agency (CDA).

The agency told the media outlet that it was notified on February 25 that two Singapore Airlines (SIA) passengers infected with measles landed in Auckland, New Zealand. Both were from the same household and flown from Hyderabad, India. They transited in Singapore for two hours before boarding an SIA flight to Auckland.

CDA investigation also revealed that these two cases remained in the transit area at Changi Airport. Associate Professor Lim Poh Lian, group director of the CDA's Communicable Disease Programmes, as reported by The Strait Times noted that the individuals were reported to have developed symptoms only while onboard the flight from Singapore to Auckland.

New Zealand media earlier reported that the two cases were detected after the individuals arrived in Auckland on flight SQ281 on February 17. The country’s public health authority began tracing passengers seated in rows 31 to 46 on the same flight, along with people who were present in the waiting area of Waitakere Hospital’s Emergency Department on February 21.

“Based on the onset of their symptoms, they were infected before transiting through Singapore and are not linked to any other known measles cases in Singapore,” Prof Lim said.

She also clarified that their time in transit through Singapore did not coincide with that of a previously reported measles case involving a passenger who had passed through Singapore en route to Los Angeles in the United States.

What Is Measles?

Measles has a high transmissibility, and high measles immunity levels are required to prevent sustained measles virus transmission.

This is why herd immunity for measles could be easily breached.

It easily spreads from one infected person to another through breathes, coughs or sneezes and could cause severe disease, complications, and even death.

Symptoms include:

  • High fever
  • Cough
  • Runny Nose
  • Rash all over the body

The most unique symptom or the early sign of measles in the Koplik spots. These are tiny white dots that look like grains of salt on red gums inside the cheeks that appear before the red rash starts to appear on a person's face and then the body.

Furthermore, the symptoms of measles are also characterized by the three Cs:

  • Cough
  • Coryza or runny nose
  • Conjunctivitis or red and water eyes

Update On The Passengers Who Landed In New Zealand

The passenger on flight SQ38 arrived at Los Angeles International Airport at about 7pm on February 9, after a roughly two-and-a-half-hour transit at Changi Airport following a flight from Cambodia.

Prof Lim said the most effective protection against measles is to be fully vaccinated before travelling. She also advised travellers to practise good hygiene, such as washing hands regularly and avoiding close contact with anyone who is unwell.

Anyone who develops symptoms like fever, rash, cough, red or watery eyes, or a runny nose should wear a mask, seek medical care promptly, and inform their doctor about their recent travel and any possible exposure to measles, she added.

In response to queries, Singapore Airlines told The Straits Times that it is working closely with the authorities but cannot share specific details due to customer confidentiality.

End of Article

Fact Check: Common Myths Around HPV Vaccine And How It Will Prevent Cervical Cancer

Updated Feb 28, 2026 | 08:00 PM IST

SummaryThe national program will use Gardasil, a quadrivalent HPV vaccine that protects against HPV types 16 and 18, which cause cervical cancer, as well as types 6 and 11. Countries with early HPV vaccine adoption have also shown large declines in HPV infection, high-grade cervical lesions, and cervical cancer incidence.
Fact Check: Common Myths Around HPV Vaccine And How It Will Prevent Cervical Cancer

Credit: Canva

In a major push towards eliminating cervical cancer from India, Prime Minister Narendra Modi today launched the nationwide Human Papillomavirus (HPV) vaccination program for girls aged 14 years.

The new vaccination drive comes as cervical cancer remains the second most common cancer among women in India, with nearly 80,000 new cases and over 42,000 deaths reported annually. As per data from the ICMR-National Cancer Registry Program (NCRP), an estimated 78,499 new cases and 42,392 deaths were reported in 2024.

Calling it a "decisive step”, the government noted that it is aimed at “strengthening the vision of ‘swasth nari’ (healthy women) while being rooted in scientific evidence, strict regulatory oversight and global best practices”.

“India's vaccination drive reflects safety, responsibility, and long-term commitment to women’s health,” it added.

The national program will use Gardasil, a quadrivalent HPV vaccine that protects against HPV types 16 and 18, which cause cervical cancer, as well as types 6 and 11.

However, social media has been rife with concerns around the safety of the vaccine, its impact on women’s reproductive health, among others.

HPV Vaccine: The Myths And Facts

Myth: HPV vaccines can cause severe side effects and even death.

Fact: The HPV vaccines come with a “confirmed strong safety record”.

“Extensive global monitoring shows a strong safety profile supported by scientific reviews. Independent evaluations have found no causal link between vaccination and chronic harm, strengthening confidence in its continued use worldwide,” the government said.

The vaccine has been licensed in India since 2008, and the new rollout follows recommendations by the World Health Organization (WHO) and approvals from the National Technical Advisory Group on Immunization (NTAGI).

“HPV vaccines have been given to hundreds of millions globally. Extensive post-marketing surveillance shows an excellent safety profile, with no causal link to serious adverse outcomes. The evidence is robust, transparent, and reassuring,” Dr. CS Pramesh, Director of the Tata Memorial Hospital, Mumbai, shared in a post on the social media platform X.

Myth: The HPV vaccine has never been used in India

Fact: The vaccine has been in use in India. It has been administered for years since 2008 with successful implementation in states like Punjab, Sikkim, and Tamil Nadu.

Myth: HPV vaccination does not prevent cervical cancer

Fact: The HPV vaccine has been proven to prevent cervical cancer

Studies show a 65 percent drop in cervical cancer cases among US women between 2012 and 2019 and an 88-89 percent reduction in precancerous lesions among Scottish women over a decade.

Countries with early HPV vaccine adoption have also shown large declines in HPV infection, high-grade cervical lesions, and cervical cancer incidence.

"Even when considering the rarest side effects, HPV vaccines are overwhelmingly safe. The protection they offer against cervical cancer far outweighs the minimal risks. Parents are encouraged to vaccinate their daughters on time," said Dr. Neena Malhotra, Professor and Head of Department, Department of Obstetrics and Gynecology, AIIMS New Delhi on X.

Myths: Are Multiple Doses Needed?

Fact: A single dose of the quadrivalent HPV vaccine is effective. It provides strong protection against HPV infection. It helps prevent cervical cancer.

“Strong global and Indian scientific evidence confirms that a single dose provides robust and durable protection when administered to girls in the recommended age group," the government said.

End of Article